Correction
Khan I, Morris S, Hackshaw A, et al. Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open 2015;5:e006733. doi: 10.1136/bmjopen-2014-006733
In figure 1, the top square currently reads ‘370 Randomised’. This should read ‘670 Randomised’ as mentioned earlier in the text.
Source: BMJ Open - Category: Journals (General) Authors: Johnston, A. Tags: 1506 Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | General Medicine | Lung Cancer | Men | Non-Small Cell Lung Cancer | Tarceva